Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.41 |
| ▸ | RXRB | P28702 | 8/20 | 0.41 |
| ▸ | RXRG | P48443 | 7/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16458934 | 0.87 | RXRA (0.40) | RXRARXRBRXRGPSEN1PSEN2 | |
| SCHEMBL4246248 | 0.84 | RXRA (0.31) | RXRARXRBRXRG | |
| SCHEMBL4251846 | 0.83 | ANPEP (0.30) | — | |
| SCHEMBL8718917 | 0.81 | PDK2 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL911318 | 0.80 | MGLL (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16086420 | 0.77 | CES2 (0.31) | AKR1C3AKR1C2 | |
| SCHEMBL1901069 | 0.69 | CNR2 (0.38) | RXRARXRBRXRGAKR1C3AKR1C2 | |
| SCHEMBL8718078 | 0.69 | PTPRC (0.40) | AKR1C3AKR1C2BACE1 | |
| SCHEMBL4243980 | 0.68 | — | — | |
| SCHEMBL8714275 | 0.66 | PDK2 (0.37) | CA1CA2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272742-A1 | IRON COMPLEXES AND METHODS FOR POLYMERIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160237184-A1 | IMINE COMPOUND, NOVEL CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER | JAPAN POLYPROPYLENE CORPORATION (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3050892-A1 | IMINE COMPOUND AND NOVEL CATALYST FOR OLEFIN POLYMERIZATION, AND METHOD FOR PRODUCING OLEFIN POLYMER | Japan Polypropylene Corporation (JP) | 2016-08-03 | — | — | EP | disclosed |
| EP-2781522-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUND, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND USING SAID CATALYST | Sumitomo Chemical Company, Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| WO-2012109343-A2 | IRON COMPLEXES AND METHODS FOR POLYMERIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237184-A1 | IMINE COMPOUND, NOVEL CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER | ODC1, MACF1, MOGAT2 | RXRA 4787/4885RXRB 4817/4885RXRG 4801/4885 |
| US-20160272742-A1 | IRON COMPLEXES AND METHODS FOR POLYMERIZATION | FTH1, TFRC, FDPS | RXRA 3772/4885RXRB 3511/4885RXRG 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.